Rebound growth of BRAF mutant pediatric glioma cells after MAPKi withdrawal is associated with MAPK reactivation and secretion of microglia-recruiting cytokines

Archive ouverte

Kocher, Daniela | Cao, Lei | Guiho, Romain | Langhammer, Melanie | Lai, Yun-Lu | Becker, Pauline | Hamdi, Hiba | Friedel, Dennis | Selt, Florian | Vonhören, David | Zaman, Julia | Valinciute, Gintvile | Herter, Sonja | Picard, Daniel | Rettenmeier, Johanna | Maass, Kendra | Pajtler, Kristian | Remke, Marc | von Deimling, Andreas | Pusch, Stefan | Pfister, Stefan | Oehme, Ina | Jones, David T.W. | Halbach, Sebastian | Brummer, Tilman | Martinez-Barbera, Juan Pedro | Witt, Olaf | Milde, Till | Sigaud, Romain

Edité par CCSD ; Springer Verlag -

International audience. Abstract Introduction Patients with pediatric low-grade gliomas (pLGGs), the most common primary brain tumors in children, can often benefit from MAPK inhibitor (MAPKi) treatment. However, rapid tumor regrowth, also referred to as rebound growth, may occur once treatment is stopped, constituting a significant clinical challenge. Methods Four patient-derived pediatric glioma models were investigated to model rebound growth in vitro based on viable cell counts in response to MAPKi treatment and withdrawal. A multi-omics dataset (RNA sequencing and LC-MS/MS based phospho-/proteomics) was generated to investigate possible rebound-driving mechanisms. Following in vitro validation, putative rebound-driving mechanisms were validated in vivo using the BT-40 orthotopic xenograft model. Results Of the tested models, only a BRAF V600E -driven model (BT-40, with additional CDKN2A/B del) showed rebound growth upon MAPKi withdrawal. Using this model, we identified a rapid reactivation of the MAPK pathway upon MAPKi withdrawal in vitro, also confirmed in vivo. Furthermore, transient overactivation of key MAPK molecules at transcriptional (e.g. FOS ) and phosphorylation (e.g. pMEK) levels, was observed in vitro. Additionally, we detected increased expression and secretion of cytokines (CCL2, CX3CL1, CXCL10 and CCL7) upon MAPKi treatment, maintained during early withdrawal. While increased cytokine expression did not have tumor cell intrinsic effects, presence of these cytokines in conditioned media led to increased attraction of microglia cells in vitro. Conclusion Taken together, these data indicate rapid MAPK reactivation upon MAPKi withdrawal as a tumor cell intrinsic rebound-driving mechanism. Furthermore, increased secretion of microglia-recruiting cytokines may play a role in treatment response and rebound growth upon withdrawal, warranting further evaluation.

Suggestions

Du même auteur

Class I HDAC inhibitor entinostat synergizes with PLK1 inhibitors in MYC-amplified medulloblastoma cells

Archive ouverte | Valinciute, Gintvile | CCSD

International audience. Purpose We and others have demonstrated that MYC-amplified medulloblastoma (MB) cells are susceptible to class I histone deacetylase inhibitor (HDACi) treatment. However, single drug treatmen...

Cross-species genomics reveals oncogenic dependencies in ZFTA/C11orf95 fusion-positive supratentorial ependymomas

Archive ouverte | Zheng, Tuyu | CCSD

International audience. Molecular groups of supratentorial ependymomas comprise tumors with ZFTA-RELA or YAP1-involving fusions and fusion-negative subependymoma. However, occasionally supratentorial ependymomas can...

Clinical outcome of pediatric medulloblastoma patients with Li–Fraumeni syndrome

Archive ouverte | Kolodziejczak, Anna | CCSD

International audience. Abstract Background The prognosis for Li–Fraumeni syndrome (LFS) patients with medulloblastoma (MB) is poor. Comprehensive clinical data for this patient group is lacking, challenging the dev...

Chargement des enrichissements...